![]() Inpatient management of acute deep vein thrombosis with or without pulmonary embolism.Prophylaxis of deep vein thrombosis (DVT) in hip replacement surgery, abdominal surgery, knee replacement surgery, or medical patients with severely limited mobility during acute illness.Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin. Two low molecular heparins are available in the United States: dalteparin and enoxaparin. Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using enoxaparin.Summarize the adverse event profile of enoxaparin use. ![]() Review the many indications for enoxaparin use.Describe the therapeutic mechanism of action of enoxaparin.This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of enoxaparin, pertinent for interprofessional team members in treating patients with conditions where this agent is indicated. It has FDA approval for the following clinical conditions - acute coronary syndromes, deep venous thrombosis (DVT) treatment and prophylaxis, treatment for pulmonary embolism (PE), venous thromboembolism (VTE) treatment, and prophylaxis in a variety of scenarios, percutaneous coronary intervention (PCI), and periprocedural anticoagulation, among others. Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |